"[Customers] are not ashamed to say, 'I'm on Ozempic
Without professional guidance, patients cannot reliably confirm product purity, adjust dosing safely, or track safety markers
The company references weight-loss outcomes associated with semaglutide, including a figure of "15-20% average body weight loss." Those figures are tied to broader clinical literature about FDA-approved branded semaglutide products studied in formal clinical trials and should not be interpreted as established outcomes for the compounded formulations dispensed through this telehealth platform
Much of the discussion surrounding Dihexa is based on laboratory and animal research, and its safety and effectiveness in humans have not been established
But the controversial ad also garnered backlash from some viewers and caught the attention of the pharma industry, lawmakers, medical experts and patient advocacy groups, who lashed the company for "deceptive" advertising and for perpetuating a stigma on obesity